Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BIONTECH : Berenberg reiterates its Buy rating

11/29/2021 | 07:17am EST

In his latest research note, analyst Zhiqiang Shu confirms his positive recommendation. The broker Berenberg is keeping its Buy rating. The target price remains set at USD 400.


© MarketScreener with dpa-AFX Analyser 2021
All news about BIONTECH SE
11:38aGerman Regulator Head Backs Pfizer-BioNTech's COVID-19 Vaccine Trial In US
MT
10:48aGerman regulator supports BioNTech/Pfizer's U.S. vaccine trial
RE
04:46aEU Commission rebuked for not disclosing texts over Pfizer vaccine deal
RE
03:01aTwo Weeks to Go Until the RNA Therapeutics Conference Takes Place
AQ
01/27Pfizer/BioNTech, Moderna COVID-19 Booster Shots Provide Protection Against Death from O..
MT
01/27European ADRs Move Higher in Thursday Trading
MT
01/27Pfizer tests omicron vaccine in humans
AQ
01/26Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study
MT
01/26Moderna starts trial for Omicron-specific booster shot
RE
01/26Health Care Down On Growth Doubts -- Health Care Roundup
DJ
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 374 M 19 372 M 19 372 M
Net income 2021 9 220 M 10 280 M 10 280 M
Net cash 2021 8 824 M 9 839 M 9 839 M
P/E ratio 2021 3,79x
Yield 2021 -
Capitalization 33 496 M 37 325 M 37 348 M
EV / Sales 2021 1,42x
EV / Sales 2022 0,89x
Nbr of Employees 2 800
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 138,69 €
Average target price 253,51 €
Spread / Average Target 82,8%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-40.05%37 325
GILEAD SCIENCES, INC.-7.35%84 382
REGENERON PHARMACEUTICALS-4.16%63 645
VERTEX PHARMACEUTICALS3.93%58 082
WUXI APPTEC CO., LTD.-12.95%47 040
GENMAB A/S-17.98%21 142